VBI Vaccines Announces Results of Annual General Meeting
25 mai 2018 16h15 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., May 25, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ("VBI" or the "Company"), a commercial-stage biopharmaceutical company developing next-generation infectious...
VBI Vaccines Announces Positive Final Phase 1 Study Results of Preventative CMV Vaccine
10 mai 2018 07h30 HE
|
VBI Vaccines, Inc.
CMV neutralizing antibodies against fibroblast cell infection induced in 100% of subjects who received the highest doseSafe and well-tolerated at all doses with no safety signals observedConference...
VBI Vaccines Announces First Quarter 2018 Financial Results and Provides Corporate Update
01 mai 2018 08h00 HE
|
VBI Vaccines, Inc.
-- Enrollment completed in PROTECT Phase 3 clinical study of Sci-B-Vac® Hepatitis B Vaccine -- -- Key upcoming milestones in 2018 for lead eVLP vaccine candidates, VBI-1501 for prevention of...
VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
19 avr. 2018 08h00 HE
|
VBI Vaccines, Inc.
More than 1,600 subjects enrolled in PROTECT studyTopline data expected mid-2019 CAMBRIDGE, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ:VBIV) (“VBI”) today announced...
VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
17 avr. 2018 08h00 HE
|
VBI Vaccines, Inc.
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modificationLow-dose study arm: enrollment completeIntermediate-dose study arm: enrollment...
VBI Vaccines Announces Voluntary Delisting from the Toronto Stock Exchange
12 mars 2018 16h15 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. ("VBI" or the "Company") (Nasdaq:VBIV) (TSX:VBV), a commercial-stage biopharmaceutical company developing next-generation...
VBI Vaccines Announces Changes to its Board of Directors
26 janv. 2018 16h15 HE
|
VBI Vaccines, Inc.
Sam Chawla, of Perceptive Advisors, to resign from VBI Board of DirectorsTomer Kariv, Chairman and CEO of The Pontifax Group, to replace Ran Nussbaum on VBI’s Board of Directors CAMBRIDGE, Mass.,...
VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901
17 janv. 2018 08h00 HE
|
VBI Vaccines, Inc.
Two-part Phase 1/2a study of VBI-1901 to enroll patients with recurrent GBM Part A: Dose escalation to enroll up to 18 patientsPart B: Subsequent extension of optimal dose to enroll up to 10...
VBI Vaccines Announces Initiation of Phase 3 Clinical Program for Sci-B-Vac® Hepatitis B Vaccine
19 déc. 2017 08h00 HE
|
VBI Vaccines, Inc.
Patient dosing commenced on December 18, 20174,800 subjects across two Phase 3 studies: PROTECT and CONSTANT 15-month program - headline data expected Q2 2019 CAMBRIDGE, Mass., Dec. 19, 2017 (GLOBE...
VBI Vaccines to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
12 déc. 2017 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI) today announced that Jeff Baxter, President and CEO, will present at the BMO Capital Markets...